Date April 3, 2007 Express Mail Label No. EM030847510US I hereby certify that, on the date indicated above, I described this paper with identified attachments and/or fee with the U.S. Postal Service and that it was addressed for a livery to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 by "Express Mail Post Office to Addressee" service.

Kim Blum	Kint Blum
Name (Print)	Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	DOI et al.)	Examiner:	Robert B. Mondesi
Application No.:	10/509,307)	Group Art Unit:	1652
Filed:	September 27, 2004)	Confirmation No.:	6726
Docket No.:	3190-066)	Customer No.:	33432

For: C-Jun Phosphorylation Inhibitors

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 CFR 1.97(b)

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

April 3, 2007

Sir:

The attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached Form PTO-SB-08. Pursuant to the current United States Patent and Trademark Office rules, no copies of U.S. Patents/Patent Application Publications are provided.

This Supplemental Information Disclosure Statement is being submitted after expiration of the three-month period following filing of the above-captioned application, but before an Office Action on the merits and before any Final Office Action or Notice of Allowance.

Should a first Office Action cross in the mail with the filing of this Supplemental Information Disclosure statement, then applicants respectfully petition under 37 C.F.R.§ 1.97(c) to consider the documents set forth in the Supplemental Information Disclosure Statement.

The above information is presented so that the Patent and Trademark Office can, in the first instance, determine any materiality thereof to the claimed invention. See 37 CFR 1.104(a) and

Second Supplemental Information Disclosure Statement

U.S. Patent Application No. 10/509,307

1.106(b) concerning the PTO duty to consider and use any such information. It is respectfully

requested that the information be expressly considered during the prosecution of this application,

and that the documents cited in the attached Form PTO-SB-08 be made of record therein and appear

on the first page of any patent to issue therefrom.

This submission does not represent that a search has been made or that no better art exists

and does not constitute an admission that each or all of the listed documents are material or

constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in

this application and applicant determines that the cited documents do not constitute "prior art" under

United States law, applicant reserves the right to present to the office the relevant facts and law

regarding the appropriate status of such documents.

Applicant further reserves the right to take appropriate action to establish the patentability of

the disclosed invention over the listed documents, should one or more of the documents be applied

against the claims of the present application.

It is believed that no fee is required to make this a complete and timely filing. However, if it

is determined that a petition or fee is required, the Commissioner is hereby authorized to charge any

fee associated with this statement to our Deposit Account No. 50-0925 and please consider this a

petition.

Respectfully submitted,

Luke A. Kilyk

Reg. No. 33,251

Atty. Docket No.: 3190-066

KILYK & BOWERSOX, P.L.L.C.

400 Holiday Court, Suite 102

Warrenton, VA 20186

Tel: (540) 428-1701 Fax: (540) 428-1720

Enclosures:

PTO-SB-08, w/12 Documents

PTO/SB/08a (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

der the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Complete if Known Substitute for form 1449A/PTO 10/509,307 **Application Number** Filing Date September 27, 2004 INFORMATION DISCLOSURE First Named Inventor DOI et al. STATEMENT BY APPLICANT Art Unit 1652 (Use as many sheets as necessary) **Examiner Name** Robert B. Mondesi 3 Attorney Docket Number 3190-066 Sheet

	U.S. PATENT DOCUMENTS						
Examiner	Cite	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
Initials*	No. ¹	Number - Kind Code ^{2 (f known)}	IVIIVI-UU-TTTT	Applicant of Cited Document			
		US-2006/0069519 A1	03-30-2006	Doi et al.			
		US-2004/0121398 A1	06-24-2004	Doi et al.			
······································		US-					
		US-					
		US-					
		US-					
	-	US-					
		US-					
		US-					
		US-					
\$11.000 1111 1111 1111 1111 1111 1111 11		US-					
		US-					
		US-					
		US-					
		US-					

	FOREIGN PATENT DOCUMENTS								
Examiner Cite No.1		Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear				
		WO 01/67299 A1	09-13-2001	Daiichi Pharmaceutical Co., Ltd.	English Abstract; see U.S. Patent Application Publication Nos. 2006/0069519 A1 and 2004/0121398 A1 for English equivalent				
***************************************				Canada a saaraa ah da akka saada wii ii balii ii saada ah ii ii bala ah ah ii saada ah ii saada ah ii saada ah		┝			
	<u> </u>					H			

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b (09-06)

Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it displays a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 1449B/PTO				Complete if Known		
				Application Number	10/509,307	
INF	ORMATION DISC	a os	SURF	Filing Date	September 27, 2004	
	ATEMENT BY AP			First Named Inventor	DOI et al.	
31/	AIEMENI DI AF	PLI	AINI	Art Unit	1652	
(Use as many sheets as necessary)				Examiner Name	Robert B. Mondesi	
Sheet	2	of	3	Attorney Docket Number	3190-066	

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²			
		KITANAKA et al., "The Diversity of Control Mechanisms for Survival and Death of Cells," MOLECULAR MEDICINE, Vol. 37, No. 4, 2000, pp. 408-418 (with English translation).				
		BEHRENS et al., "Amino-terminal phosphorylation of c-Jun regulates stress-induced apoptosis and cellular proliferation," NATURE GENETICS, Vol. 21, March 1999, pp. 326-329.	***************************************			
		YANG et al., "Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene," NATURE, Vol. 389, October 23, 1997, pp. 865-870.	3			
		KOYANO et al., "A novel Jun N-terminal kinase (JNK)-binding protein that enhances the activation of JNK by MEK kinase 1 and TGF-β-activated kinase 1," FEBS LETTERS, No. 457, 1999, pp. 385-388.				
		GEKAKIS et al., "Role of the CLOCK Protein in the Mammalian Circadian Mechanism," SCIENCE, Vol. 280, June 5, 1998, pp. 1564-1569.	***************************************			
		BUNGER et al., "Mop3 Is an Essential Component of the Master Circadian Pacemaker in Mammals," CELL, Vol. 103, December 22, 2000, pp. 1009-1017.	-			
	•	NARISAWA et al., "Cloning of the holocarboxylase synthetase cDNA and identification of mutations prevalent in Japanese HCS-deficient patients," JAPANESE JOURNAL OF CLINICAL MEDICINE, No. 54(1), 1996, pp. 259-267 (Summary in English).				
		IKEDA et al., "cDNA Cloning and Tissue-Specific Expression of a Novel Basic Helix-Loop-Helix/PAS Protein (BMAL1) and Identification of Alternatively Spliced Variants with Alternative Translation Initiation Site Usage," BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, No. 233, 1997, pp. 258-264				
***************************************		SUZUKI et al., "Isolation and characterization of mutations in the human holocarboxylase synthetase cDNA," NATURE GENETICS, Vol. 8, October 1994, pp. 122-128.				
7444-444		YASUDA et al., "Triggering of neuronal cell death by accumulation of activated SEK1 on nuclear polyglutamine aggregations in PML bodies," GENES TO CELLS, No. 4, 1999, pp. 743-756.				

Examiner	Date
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here it English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known		
Jubstitu	Substitute for form 1443D/F TO			Application Number	10/509,307	
INF	ORMATION DISC	1 09	SURF	Filing Date	September 27, 2004	
	STATEMENT BY APPLICANT			First Named Inventor	DOI et al.	
317				Art Unit	1652	
(Use as many sheets as necessary)		Examiner Name	Robert B. Mondesi			
Sheet	3	of	3	Attorney Docket Number	3190-066	

Examiner			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
		URA et al., "Hot Spot with respect to Signal Transduction, The JNK pathway and its roles in the regulation of cell death," EXPERIMENTAL MEDICINE, Vol. 19, No. 14, September 2001, pp. 1839-1844 (with English translation).	

Examiner	Date
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.